10-Q: Paysign Reports Strong Q3 2024 Results Driven by Pharma and Plasma Growth

Paysign's Q3 2024 results show significant revenue growth, particularly in the pharma and plasma sectors, leading to increased profitability.

Summary

• Paysign's Q3 2024 revenue increased by 23% year-over-year to $15.26 million, driven by growth in the plasma and pharma industries.
• Plasma industry revenue grew by 3.4% to $11.44 million, while pharma industry revenue surged by 219.1% to $3.27 million.
• The company's gross profit increased by 33.8% to $8.47 million, with a gross margin of 55.5%.
• Operating expenses rose by 35.6% to $7.78 million, primarily due to increased compensation, benefits, and technology investments.
• Net income for the quarter was $1.44 million, a 30.5% increase compared to the same period last year.
• For the nine months ended September 30, 2024, total revenue was $42.78 million, a 27.4% increase year-over-year.
• Net income for the nine-month period was $2.44 million, a significant improvement from $0.84 million in the prior year.
• The company's cash and restricted cash totaled $110.57 million as of September 30, 2024.
• Paysign repurchased 100,000 shares of its common stock during the quarter at a weighted average price of $3.60 per share.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong financial results, particularly in revenue growth and profitability. The company is also investing in future growth and has a solid cash position. However, there are some concerns about increasing operating expenses and ongoing legal proceedings.

Positives

• The company experienced significant revenue growth in both the plasma and pharma sectors.
• Gross profit and net income showed substantial increases compared to the previous year.
• Paysign's gross margin improved to 55.5% in Q3 2024.
• The company's platform is designed for seamless integration with client systems.
• Paysign's architecture is known for its cross-platform compatibility, flexibility, and scalability.
• The company is investing in technology improvements, sales and marketing, cybersecurity, and regulatory compliance.
• Paysign has a strong cash position with $10.29 million in unrestricted cash.
• The company believes its available cash and forecast revenues will be sufficient to sustain operations for the next 24 months.

Negatives

• Operating expenses increased significantly, primarily due to higher compensation and technology costs.
• The company experienced increased fraud charges and customer care expenses.
• There was an increase in network fees due to higher ATM usage and transaction fees.
• The company is involved in ongoing legal proceedings, including shareholder derivative actions.

Risks

• The company faces risks related to its cash and cash equivalents held in bank accounts, which may exceed federally insured limits.
• Paysign has a concentration of accounts receivable risk with two pharma program customers representing a significant portion of the balance.
• The company is subject to litigation risks, including securities class action and shareholder derivative actions.
• The company's future performance is subject to various market and economic conditions.
• The company's estimates and assumptions could differ from actual results, which could have a material effect on the reported amounts of the company's financial position and results of operations.

Future Outlook

Paysign plans to continue investing in technology, sales, marketing, cybersecurity, and regulatory compliance. The company also evaluates raising capital to diversify into new market verticals, but believes it can support existing business and expand into new markets using internally generated funds. Paysign believes its available cash and forecast revenues will be sufficient to sustain operations for the next 24 months.

Management Comments

• Management believes that gross dollar volume loaded on cards and conversion rates are primary indicators of quarterly and annual revenues.
• Management also reviews key performance indicators such as revenues, gross profit, operational expenses as a percent of revenues, cardholder participation, and EBITDA.
• Management considers certain non-GAAP measures, such as EBITDA and Adjusted EBITDA, to be useful in evaluating operating performance.

Industry Context

The prepaid card market in the United States has experienced significant growth due to consumers and merchants embracing improved technology, greater convenience, more product choices, and greater flexibility. Paysign is positioned to capitalize on this trend with its vertically integrated platform and diverse product offerings.

Comparison to Industry Standards

• Paysign's revenue growth of 23% in Q3 2024 is strong compared to the overall payment processing industry, which is experiencing moderate growth.
• The 219.1% growth in pharma revenue is exceptional and indicates a successful expansion into this market segment.
• Paysign's gross margin of 55.5% is competitive with other payment processors, but may be lower than some specialized software companies.
• The company's investment in technology and platform development is consistent with industry trends towards digital transformation and enhanced security.
• Paysign's focus on corporate incentive and expense prepaid card products aligns with the growing demand for these solutions in various market verticals.
• Companies like Wex Inc. and FleetCor Technologies, Inc. also operate in the corporate payments space, but Paysign's focus on prepaid cards and specific verticals differentiates it.
• Global Payments Inc. and Fiserv, Inc. are larger payment processors, but Paysign's niche focus allows it to compete effectively in its target markets.

Legal Proceedings

• The company is involved in ongoing legal proceedings, including three securities class action complaints and four stockholder derivative actions.
• A settlement was reached in the securities class action, with the settlement amount covered by the company's directors-and-officers insurance policy.
• The four shareholder derivative actions have been agreed to be settled, with the settlement including certain corporate therapeutics and payment of attorneys fees by the company's insurer.

Stakeholder Impact

• Shareholders will likely view the strong financial results and growth prospects positively.
• Employees may benefit from the company's continued growth and investment in technology.
• Customers will likely benefit from the company's improved platform and expanded product offerings.
• Suppliers may see increased business opportunities as the company continues to grow.
• Creditors may view the company's strong cash position and profitability favorably.

Next Steps

• The company plans to continue investing in technology improvements, sales and marketing, cybersecurity, fraud, customer service, and regulatory compliance.
• Paysign will continue to evaluate raising capital to enable diversification into new market verticals.
• The company will continue to monitor the health and soundness of its bank relationships.

Key Dates

Keywords

prepaid cards, payment processing, plasma industry, pharma industry, financial results, revenue growth, EBITDA, gross profit, net income, card programs, financial technology, fintech